Journal article

Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study

Kaja Tikk, Disorn Sookthai, Renee T Fortner, Theron Johnson, Sabina Rinaldi, Isabelle Romieu, Anne Tjonneland, Anja Olsen, Kim Overvad, Francoise Clavel-Chapelon, Laura Baglietto, Heiner Boeing, Antonia Trichopoulou, Pagona Lagiou, Dimitrios Trichopoulos, Giovanna Masala, Vittorio Krogh, Rosario Tumino, Fulvio Ricceri, Amalia Mattiello Show all

Breast Cancer Research | BIOMED CENTRAL LTD | Published : 2015

Grants

Awarded by Norwegian Cancer Society


Awarded by Spanish Ministry of Health (ISCIII RETICC)


Awarded by Regional Governments of Andalucia, Asturias, Basque Country, Murcia


Awarded by Navarra, ISCIII RETIC (Spain)


Awarded by Cancer Research UK


Awarded by Medical Research Council


Awarded by National Institute for Health Research


Funding Acknowledgements

The coordination of EPIC is financially supported by the European Commission (DGSANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue contre le Cancer, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Italian Association for Research on Cancer (AIRC) and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Norwegian Research Council, Norwegian Cancer Society, ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health. (Norway); Health Research Fund (FIS), The Spanish Ministry of Health (ISCIII RETICC RD06/0020/0091) and the Catalan Institute of Oncology, Regional Governments of Andalucia, Asturias, Basque Country, Murcia (no 6236) and Navarra, ISCIII RETIC (RD06/0020; Spain); Swedish Cancer Society, Swedish Scientific Council and Regional Government of Skane and Vasterbotten (Sweden); Cancer Research UK, Medical Research Council (United Kingdom).